One of the most promising developments highlighted through clinical trials is the rise of targeted therapies. Unlike conventional treatments that affect both healthy and cancerous cells, targeted therapies focus on specific genetic mutations that drive tumor growth. Many pediatric brain tumors, such as gliomas and medulloblastomas, contain unique genetic markers that researchers can target with precision drugs. Early trial results show that these therapies can slow tumor growth and, in some cases, shrink tumors with fewer side effects than chemotherapy.
